Ortho Dermatologics to Present New Data at the 2022 Innovations in Dermatology Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Bausch Health Companies (BHC) PT Lowered to $14 at Stifel
November 3, 2022 1:23 PM EDTStifel analyst Annabel Samimy lowered the price target on Bausch Health Companies (NYSE: BHC) to $14.00 (from $15.00) while maintaining a Buy rating following results.
The analyst commented, "Remaining committed to the BLCO separation, BHC reported a lower 3Q22, with revenues of $2,046mn/Cons.... More
